Arrowhead claims safety edge over Ionis as triglyceride battle draws closer

Arrowhead's Redemplo shows a stronger safety edge than Ionis' Tryngolza in new Phase 3 sHTG data, sharpening a fast-approaching triglyceride-drug rivalry.

Raccontata daendpoints.news